/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

E

Elizabeth K. Duperret

Arvinas (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

69

Papers

1.9K

Citations

21

h-index

23

i10-index

Elizabeth K. Duperret is an academic researcher from Arvinas (United States). The author has contributed to research in topics: Immunotherapy and Immune Responses & CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 21, co-authored 59 publications.

ORCID: 0000-0003-1640-4205

Research Topics

Immunotherapy and Immune Responses CAR-T cell therapy research Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction RNA Interference and Gene Delivery

Papers by this author

works

Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer

2017 · Nature Communications · 286 citations

https://doi.org/10.1038/s41467-017-02186-9

Filippo Veglia Vladimir A. Tyurin Dariush Mohammadyani Maria Blasi

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine

2016 · npj Vaccines · 136 citations

https://doi.org/10.1038/npjvaccines.2016.21

Kar Muthumani Bryan D. Griffin Sangya Agarwal Sagar B. Kudchodkar

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT

2017 · Molecular Therapy · 45 citations

https://doi.org/10.1016/j.ymthe.2017.11.010

Elizabeth K. Duperret Megan C. Wise Aspen Trautz Daniel O. Villarreal

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity

2019 · JCI Insight · 40 citations

https://doi.org/10.1172/jci.insight.126086

Alfredo Perales‐Puchalt Elizabeth K. Duperret Xue Yang Patricia Hernández

MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NA&IUML;VE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY

2024 · The Journal of Urology · 0 citations

https://doi.org/10.1097/01.ju.0001009428.69695.82.19

Neal D. Shore Joshua M. Lang Daniel M. Geynisman Tyler F. Stewart

Abstract PS2-07-24: Circulating tumor DNA (ctDNA) biomarker analyses of a phase 1/2 study evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)

2026 · Clinical Cancer Research · 0 citations

https://doi.org/10.1158/1557-3265.sabcs25-ps2-07-24

S. A. Wander H. S. Han E. P. Hamilton S. A. Hurvitz

Research topics

topics

Immunotherapy and Immune Responses

CAR-T cell therapy research

Cancer Immunotherapy and Biomarkers

Immune Cell Function and Interaction

RNA Interference and Gene Delivery

Chat about Author

Papers

Chat

Click to start Chat